First-Generation GLP-1 Drugs May Help Lower Risk of Obesity-Related Cancers
First-generation GLP-1 weight-loss drugs could help reduce the risk of obesity-related cancers, new research shows.
These medications have been around longer than the newer, better-known GLP-1 drugs, such as Ozempic, but they work in similar ways.
Experts say a healthy lifestyle that includes a well-balanced diet, regular exercise, and adequate sleep is an important component of any weight-loss strategy.
A new study indicates that certain GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers.
The study, conducted by researchers at Clalit Health Services in Israel, was published on May 11 in the journal eClinicalMedicine. The findings were presented at this year's European Congress on Obesity, May 11–14 in Malaga, Spain.
In their study, the scientists reported that the direct effect of the GLP-1 drugs liraglutide, exenatide, and dulaglutide was 41% more effective at preventing obesity-related cancers beyond just weight loss.
The researchers said they aren't certain why these types of GLP-1 drugs have anticancer properties, but they said the lower risk could come from mechanisms such as reducing inflammation in the body.
Tulsi Sharma, MD, an assistant professor of medicine at the University of California San Francisco's regional campus in Fresno, said this latest research bolsters the already-known benefits of these medications. Sharma wasn't involved in the study.
'GLP-1 agonists represent a major breakthrough in weight management and diabetes treatment, offering hope for those who have faced significant challenges in achieving and maintaining a healthy weight,' she told Healthline. 'They have been linked to reducing inflammation and supporting metabolic function, and this makes them more than just weight-loss aids; they are transformative tools for long-term health.'
Anticancer benefits of GLP-1 drugs
The Clalit Health Services researchers analyzed the health records of 6,356 people.
The subjects were at least 24 years old with obesity and type 2 diabetes. None of them had a prior history of cancer.
Just over 60% of the participants were female. The average age was 52, and the mean body mass index (BMI) was 41.5, above the minimum threshold of 30 for obesity.
Half of the subjects were treated with one of the GLP-1 drugs for at least 6 months, and the other half had bariatric surgery. The time period for these treatments was 2010 to 2018.
The participants had a mean follow-up period of more than 7 years.
In all, 298 participants were diagnosed with obesity-related cancer within the follow-up period. There were 150 cancer diagnoses in the group that had bariatric surgery and 148 in the group that took the GLP-1 drugs.
The most common cancer diagnosis was postmenopausal breast cancer, followed by colorectal cancer and cancer of the uterus.
The researchers said the similar results in both groups indicates that the anti-cancer benefits of these GLP-1 medications extends beyond the benefits of weight loss alone.
The scientists acknowledged that their research is an observational study and future randomized trials and larger studies need to be conducted.
Sun Kim, MD, an associate professor of medicine at Stanford University in California, said that she would have liked a third 'control' group added to the study who did not take GLP-1 drugs or had bariatric surgery. Kim wasn't involved in the new study.
She also noted that 65% of the group who underwent surgery were using insulin, while only 9% of participants taking GLP-1 drugs were using insulin.
'This is a huge difference. Individuals with diabetes who require insulin can be a different group than those who do not require insulin,' Kim told Healthline.
What to know about GLP-1 drugs
Glucagon-like peptide-1 receptor agonists (GLP-1s) work by mimicking a hormone in the body that helps regulate blood sugar levels and promotes satiety.
The medications studied in the new research are first-generation drugs that have been used as treatments longer than the newer, better-known medications, such as Ozempic.
All of these medications are liquid solutions that are injected under the skin.
Liraglutide is sold under the brand names Victoza and Saxenda. Victoza is approved for treating type 2 diabetes, while Saxenda can be prescribed for weight loss. A 2023 study reported that liraglutide may help improve brain function in people with obesity.
Exenatide in its extended-release form is sold under the brand name Bydureon BCise. It is prescribed along with a healthy diet and regular exercise to treat type 2 diabetes.
Dulaglutide is sold under the brand name Trulicity. It is prescribed for people with type 2 diabetes to help reduce blood sugar levels and lower the risk of heart attack and stroke.
These older medications work in a similar fashion to the newer GLP-1 drugs, although studies have indicated the newer drugs may also benefit brain and heart health.
One class of the newer GLP-1 medications uses the active ingredient semaglutide. They are sold under different brand names. Ozempic and Rybelsus have been approved to treat type 2 diabetes. Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.
The other newer group uses the active ingredient tirzepatide. Mounjaro is approved to treat type 2 diabetes. Zepbound is approved for use in weight management. These medications are available only as injections.
Sharma said the reduction of inflammation is a key to all these medications.
'Excess body fat produces inflammatory molecules that can promote tumor growth, and these medications help regulate metabolic pathways, reducing systemic inflammation,' she said. 'They also improve insulin sensitivity, which can lower the risk of insulin-resistant conditions linked to cancer.'
Health effects of obesity
Obesity is a chronic health condition.
Unhealthy eating patterns and a sedentary lifestyle may lead to obesity. Other factors like genetics, aging, lack of sleep, and stress may also play a role.
The condition, which may progressively worsen over time, is associated with a higher risk of developing type 2 diabetes, heart disease, and certain cancers. Obesity could also lead to other health complications, such as:
'Obesity adversely affects every organ in the body,' Mir Ali, MD, a general surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, told Healthline. Ali wasn't involved in the new study.
'Some of these effects are direct damage to organs, but other effects can be due to chronic inflammation or significant hormonal changes. Therefore, someone who is severely obese is greatly reducing their life expectancy.'
Tracey Childs, MD, the chief of surgery at Providence Saint John's Health Center and adjunct associate professor of surgery at Saint John's Cancer Institute in California, said there are also the psychological and social aspects of obesity that can inhibit a person's desire to exercise or be in public settings. Childs was likewise not involved in the new research.
'It can be difficult to get out and around,' she told Healthline.
How to safely and effectively lose weight
Experts say a multi-faceted plan is the best approach to weight management.
'Many tools are available to help patients that have significant weight to lose, including, but not limited to weight loss medications and surgery,' Ali said.
'Patients who are significantly overweight have a very low long-term success rate with just dieting and exercise, and often require these tools to help them lose weight. I also advise patients that no matter what tool is used, they need to make healthier food and lifestyle choices to have long-term, sustainable results.'
'For those struggling with weight management, it's important to approach the journey with patience and self-compassion,' added Sharma. 'Start by focusing on sustainable lifestyle changes — prioritizing whole, nutrient-rich foods, regular movement, and healthy sleep habits.'
Childs noted that GLP-1 drugs can sometimes make weight loss seem relatively easy and lead to weight regain after a person stops using these medications.
Childs stresses to patients that they still need to adopt healthy lifestyles and partner with someone who will exercise with them or check in on them.
'Cooperation and accountability are important,' she said.
Kim agreed that an overall focus on health is the best strategy for weight management.
'I think it is important for individuals struggling with obesity to have a comprehensive evaluation to understand the effects of excess weight on their health,' she said. 'I try to emphasize with my patient that we are working on improving their health versus fixation on weight loss.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
15 minutes ago
- Associated Press
Bloomberg's War on Harm Reduction Faces Consumer Backlash at Tobacco Conference
DUBLIN, IRELAND / ACCESS Newswire / June 23, 2025 / On the eve of the World Conference on Tobacco Control (WCTC), a lightshow illuminated the conference centre in Dublin, sending a clear message: millions of consumers are being left out of the conversation on global tobacco and nicotine policy. The event, organised by the World Vapers' Alliance, launched the " Voices Unheard - Consumers Matter! " campaign to highlight the ongoing marginalisation of those most affected by tobacco control decisions. With COP11 in Geneva on the horizon, the campaign underscores the urgent need for consumer representation in policymaking. While hundreds of experts and officials discuss regulations behind closed doors, the light show symbolises the voices of countless adults who have successfully quit smoking with safer alternatives, yet remain unheard in critical policy debates. Michael Landl, Director of the World Vapers' Alliance, criticised the influence of powerful figures such as Michael Bloomberg, whose support for prohibitionist policies often sidelines consumer perspectives. 'Policymakers must listen to those whose lives are directly impacted by these decisions,' Landl said. 'Evidence, not ideology or the influence of wealthy donors, should guide regulations.' The campaign also addresses recent calls from the World Health Organization for bans on flavoured nicotine products, which advocates argue would deny adults access to life-saving alternatives. Alberto Gómez Hernández, Policy and Advocacy Manager for the WVA, emphasised, 'Banning flavours is not about protection-it's about denying adults the tools they need to quit smoking.' The World Vapers' Alliance continues to call for evidence-based harm reduction policies and genuine consumer inclusion as the world prepares for COP11. For media enquiries, please contact: Michael Landl [email protected] +436648412958 High-quality pictures can be found here. More information about flavour bans: More about the WVA's demands: SOURCE: World Vapers' Alliance press release
Associated Press
25 minutes ago
- Associated Press
Crash dummies used in car safety tests are still modeled after men despite higher risks for women
Maria Weston Kuhn had one lingering question about the car crash that forced her to have emergency surgery during a vacation in Ireland: Why did she and her mother sustain serious injuries while her father and brother, who sat in the front, emerge unscathed? 'It was a head-on crash and they were closest to the point of contact,' said Kuhn, now 25, who missed a semester of college to recover from the 2019 collision that caused her seat belt to slide off her hips and rupture her intestines by pinning them against her spine. 'That was an early clue that something else was going on.' When Kuhn returned home to Maine, she found an article her grandma had clipped from Consumer Reports and left on her bed. Women are 73% more likely to be injured in a frontal crash, she learned, yet the dummy used in vehicle tests by the National Highway Traffic Safety Administration dates back to the 1970s and is still modeled almost entirely off the body of a man. A survivor becomes an activist Kuhn, who is starting law school at New York University this fall, took action and founded the nonprofit Drive US Forward. Its aim was to raise public awareness and eventually encourage members of Congress to sign onto a bill that would require NHTSA to incorporate a more advanced female dummy into its testing. The agency has the final word on whether cars get pulled from the market, and the kind of dummy used in its safety tests could impact which ones receive coveted five-star ratings. 'It seems like we have an easy solution here where we can have crash test dummies that reflect an average woman as well as a man,' Sen. Deb Fischer, a Nebraska Republican who has introduced the legislation the past two sessions, told The Associated Press. Senators from both parties have signed onto Fischer's 'She Drives Act,' and the transportation secretaries from the past two presidential administrations have expressed support for updating the rules. But for various reasons, the push for new safety requirements has been moving at a sluggish pace. That's particularly true in the U.S., where much of the research is happening and where around 40,000 people are killed each year in car crashes. Evolution of a crash test dummy The crash test dummy currently used in NHTSA five-star testing is called the Hybrid III, which was developed in 1978 and modeled after a 5-foot-9, 171-pound man (the average size in the 1970s but about 29 pounds lighter than today's average). What's known as the female dummy is essentially a much smaller version of the male model with a rubber jacket to represent breasts. It's routinely tested in the passenger seat or the back seat but seldom in the driver's seat, even though the majority of licensed drivers are women. 'What they didn't do is design a crash test dummy that has all the sensors in the areas where a woman would be injured differently than a man,' said Christopher O'Connor, president and CEO of the Farmington Hills, Michigan-based Humanetics Group, which has spent more than a decade developing and refining one. A female dummy from Humanetics equipped with all of the available sensors costs around $1 million, about twice the cost of the Hybrid used now. But, O'Connor says, the more expensive dummy far more accurately reflects the anatomical differences between the sexes — including in the shape of the neck, collarbone, pelvis, and legs, which one NHTSA study found account for about 80% more injuries by women in a car crash compared to men. Such physical dummies will always be needed for vehicle safety tests, and to verify the accuracy of virtual tests, O'Connor said. Europe incorporated the more advanced male dummy developed by Humanetics' engineers, the THOR 50M (based on a 50th percentile man), into its testing procedures soon after Kuhn's 2019 crash in Ireland. Several other countries, including China and Japan, have adopted it as well. But that model and the female version the company uses for comparison, the THOR 5F (based on a 5th percentile woman), have been met with skepticism from some American automakers who argue the more sophisticated devices may exaggerate injury risks and undercut the value of some safety features such as seat belts and airbags. A debate over whether more sensors mean more safety Bridget Walchesky, 19, had to be flown to a hospital, where she required eight surgeries over a month, after a 2022 crash near her home in Sheboygan, Wisconsin, that killed her friend, who was driving. While acknowledging the seat belt likely saved her life, Walchesky said some of the injuries — including her broken collarbone — were the result of it pinning her too tightly, which she views as something better safety testing focused on women could improve. 'Seat belts aren't really built for bodies on females,' Walchesky said. 'Some of my injuries, the way the force hit me, they were probably worsened.' The Alliance for Automotive Innovation, an industry trade group, said in a statement to the AP that the better way to ensure safety — which it called its top priority — is through upgrades to the existing Hybrid dummy rather than mandating a new one. 'This can happen on a faster timeline and lead to quicker safety improvements than requiring NHTSA to adopt unproven crash test dummy technology,' the alliance said. Humanetics' THOR dummies received high marks in the vehicle safety agency's early tests. Using cadavers from actual crashes to compare the results, NHTSA found they outperformed the existing Hybrid in predicting almost all injuries — including to the head, neck, shoulders, abdomen and legs. A separate review by the Insurance Institute for Highway Safety, a research arm funded by auto insurers, was far more critical of the dummy's ability to predict chest injuries in a frontal crash. Despite the vast expansion in the number of sensors, the insurance institute's testing found, the male THOR dummy was less accurate than the current Hybrid dummies, which also had limitations. 'More isn't necessarily better,' said Jessica Jermakian, senior vice president for vehicle research at IIHS. 'You also have to be confident that the data is telling you the right things about how a real person would fare in that crash.' The slow pace of changing the rules NHTSA's budget plan commits to developing the female THOR 5F version with the ultimate goal of incorporating it into the testing. But there could be a long wait considering the THOR's male version adopted by other countries is still awaiting final approval in the U.S. A 2023 report by the Government Accountability Office, which conducts research for Congress, cited numerous 'missed milestones' in NHTSA's development of various crash dummy enhancements — including in the THOR models. Kuhn acknowledges being frustrated by the slow process of trying to change the regulations. She says she understands why there's reluctance from auto companies if they fear being forced to make widespread design changes with more consideration for women's safety. 'Fortunately, they have very skilled engineers and they'll figure it out,' she said.
Yahoo
an hour ago
- Yahoo
GPs can prescribe weight loss jabs on the NHS from today - but strict eligibility criteria in place
GPs will be able to prescribe weight loss jabs on the NHS from today. About 220,000 people with the "greatest need" are set to receive Mounjaro - with strict criteria for the first year of the rollout. Initially, only those with a body mass index of over 40 who have at least four other health problems linked to obesity will be eligible. Some doctors have raised concerns about the additional workload this new programme will bring, while pharmacists fear it could lead to supply shortages. While an estimated 1.5 million people are now taking weight loss drugs across the UK, they could previously only be accessed through specialist services or private prescriptions. Dr Claire Fuller from NHS England said: "We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health - and greater access to weight loss drugs will make a significant difference to the lives of those people." She added: "While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional." The chairwoman of the Royal College of GPs welcomed NHS England's decision to pursue a phased rollout, and said current workloads must be factored in to ensure the jabs can be prescribed safely. Professor Kamila Hawthorne went on to say: "While weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. "We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later." Read more from Sky News:UK and NATO allies to boost defence spending Her remarks were echoed by the National Pharmacy Association's chairman Olivier Picard, who says "prescribing these medications alone misses the point". He argued that they need to be part of a comprehensive strategy that includes lifestyle coaching, exercise and nutritional guidance - but many GPs currently "lack the bandwidth" to provide this support. "As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends - simply because the foundational lifestyle changes weren't addressed," Mr Picard added. Estimates suggest about 29% of the adult population is obese. Health Secretary Wes Streeting says the government "is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay".
